Dyne Therapeutics (DYN) announced additional positive data from the ongoing Phase 1/2 Deliver clinical trial of zeleciment rostudirsen, z-rostudirsen, in individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. These data are being presented in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference being held March 8-11, 2026, in Orlando, FL, which is available in the Scientific Publications & Presentations section of Dyne’s website along with all of Dyne’s other posters being presented at the conference.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Controversial Prasad leaving FDA, NYT reports
- Dyne Therapeutics price target lowered to $47 from $50 at Morgan Stanley
- Dyne Therapeutics price target lowered to $50 from $60 at H.C. Wainwright
- Dyne Therapeutics reports Q4 EPS (76c), consensus (76c)
- Dyne Therapeutics announces upcoming presentations at MDA Conference